{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T14:24:55Z","timestamp":1774362295793,"version":"3.50.1"},"reference-count":45,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2009,8,1]],"date-time":"2009-08-01T00:00:00Z","timestamp":1249084800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,8,1]],"date-time":"2009-08-01T00:00:00Z","timestamp":1249084800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2009,8]]},"DOI":"10.3816\/cgc.2009.n.016","type":"journal-article","created":{"date-parts":[[2009,8,19]],"date-time":"2009-08-19T21:04:30Z","timestamp":1250715870000},"page":"E16-E23","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["Predictive Value of Urinary Interleukin-8 Cutoff Point for Recurrences After Transurethral Resection Plus Induction Bacillus Calmette-Gu\u00e9rin Treatment in Non\u2013Muscle-Invasive Bladder Tumors"],"prefix":"10.3816","volume":"7","author":[{"given":"Levent","family":"Sagnak","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hamit","family":"Ersoy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ugur","family":"Ozok","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bugra","family":"Senturk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hakan","family":"Ercil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gul","family":"Bahar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evrim","family":"Ozturk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.3816\/CGC.2009.n.016_bib1","unstructured":"Guideline for the management of nonmuscle invasive bladder cancer: 2007 update. American Urological Association Education and Research, Inc., 2007."},{"key":"10.3816\/CGC.2009.n.016_bib2","first-page":"623","article-title":"Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials","volume":"50","author":"Sylvester","year":"2006","journal-title":"Eur Urol"},{"key":"10.3816\/CGC.2009.n.016_bib3","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/S0022-5347(17)58737-6","article-title":"Intracavitary bacillus Calmette-Guerin in the treatment of superficial bladder tumors","volume":"116","author":"Morales","year":"1976","journal-title":"J Urol"},{"key":"10.3816\/CGC.2009.n.016_bib4","first-page":"353:1689","article-title":"BCG immunotherapy of bladder cancer: 20 years on","volume":"15","author":"Alexandroff","year":"1999","journal-title":"Lancet"},{"key":"10.3816\/CGC.2009.n.016_bib5","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0022-5347(05)67707-5","article-title":"Maintance bacillus Calmette-Guerin immunotherapy for recurrent Ta, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study","volume":"163","author":"Lamm","year":"2000","journal-title":"J Urol"},{"key":"10.3816\/CGC.2009.n.016_bib6","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1097\/01.ju.0000073852.24341.4a","article-title":"Immune mechanisms in bacillus Calmette-Guerin immunotherapy for superficial bladder cancer","volume":"170","author":"B\u00f6hle","year":"2003","journal-title":"J Urol"},{"key":"10.3816\/CGC.2009.n.016_bib7","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1016\/S0022-5347(05)64273-5","article-title":"Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials","volume":"168","author":"Sylvester","year":"2002","journal-title":"J Urol"},{"key":"10.3816\/CGC.2009.n.016_bib8","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1200\/JCO.1995.13.6.1404","article-title":"Intravesical bacillus Calmette-Gu\u00e9rin therapy prevents tumor progression and death from superficial bladder cancer: tenyear follow-up of a prospective randomized trial","volume":"13","author":"Herr","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.3816\/CGC.2009.n.016_bib9","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S0065-2776(08)60791-9","article-title":"Neutrophil-derived proteins: selling cytokines by the pound","volume":"73","author":"Cassatella","year":"1999","journal-title":"Adv Immunol"},{"key":"10.3816\/CGC.2009.n.016_bib10","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/1043-4666(89)91043-0","article-title":"Interleukin 8 and MCAF: novel inflammatory cytokines inducible by IL 1 and TNF","volume":"1","author":"Matsushima","year":"1989","journal-title":"Cytokine"},{"key":"10.3816\/CGC.2009.n.016_bib11","doi-asserted-by":"crossref","first-page":"2792","DOI":"10.1172\/JCI118734","article-title":"Inhibition of interleukin-8 reduces tumorigenesis of human non-small cell lung cancer in SCID mice","volume":"97","author":"Arenberg","year":"1996","journal-title":"J Clin Invest"},{"key":"10.3816\/CGC.2009.n.016_bib12","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1126\/science.1281554","article-title":"Interleukin-8 as a macrophage-derived mediator of angiogenesis","volume":"258","author":"Koch","year":"1992","journal-title":"Science"},{"key":"10.3816\/CGC.2009.n.016_bib13","first-page":"808","article-title":"Inhibition of basic fibroblast growth factor expression, angiogenesis, and growth of human bladder carcinoma in mice by systemic interferon-alpha administration","volume":"58","author":"Dinney","year":"1998","journal-title":"Cancer Res"},{"key":"10.3816\/CGC.2009.n.016_bib14","first-page":"518","article-title":"Soluble factors levels in the initial staging of high-grade non-Hodgkin's lymphomas","volume":"77","author":"Stasi","year":"1992","journal-title":"Haematologica"},{"key":"10.3816\/CGC.2009.n.016_bib15","first-page":"3242","article-title":"Expression of interleukin 8 correlates with the metastatic potential of human melanoma cells in nude mice","volume":"54","author":"Singh","year":"1994","journal-title":"Cancer Res"},{"key":"10.3816\/CGC.2009.n.016_bib16","first-page":"9","article-title":"Differential expression of progression-related genes in the evolution of superficial to invasive transitional cell carcinoma of the bladder","volume":"8","author":"Izawa","year":"2001","journal-title":"Oncol Rep"},{"key":"10.3816\/CGC.2009.n.016_bib17","first-page":"2290","article-title":"Interleukin 8 expression regulates tumorigenicity and metastasis in human bladder cancer","volume":"60","author":"Inoue","year":"2000","journal-title":"Cancer Res"},{"key":"10.3816\/CGC.2009.n.016_bib18","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/jcb.240501322","article-title":"Intravesical BCG: current results, natural history and implications for urothelial cancer prevention","volume":"16I","author":"Herr","year":"1992","journal-title":"J Cell Biochem Suppl"},{"key":"10.3816\/CGC.2009.n.016_bib19","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1097\/00000478-199812000-00001","article-title":"The World Heath Organization\/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee","volume":"22","author":"Epstein","year":"1998","journal-title":"Am J Surg Pathol"},{"key":"10.3816\/CGC.2009.n.016_bib20","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.eururo.2008.04.051","article-title":"EAU Guidelines for non-muscleinvasive urothelial carcinoma of the bladder","volume":"54","author":"Babjuk","year":"2008","journal-title":"Eur Urol"},{"key":"10.3816\/CGC.2009.n.016_bib21","series-title":"Nonparametric Statistics for the Behavioral Sciences","first-page":"174","article-title":"The Friedman two-way analysis of variance","author":"Siegel","year":"1988"},{"key":"10.3816\/CGC.2009.n.016_bib22","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1136\/bmj.310.6973.170","article-title":"Multiple significance tests: the Borfeoni method","volume":"310","author":"Bland","year":"1995","journal-title":"BMJ"},{"key":"10.3816\/CGC.2009.n.016_bib23","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1136\/bmj.316.7139.1236","article-title":"What's wrong with Borfeoni Adjustments","volume":"316","author":"Perneger","year":"1998","journal-title":"BMJ"},{"key":"10.3816\/CGC.2009.n.016_bib24","series-title":"Model development. Applied Survival Analysis","first-page":"159","author":"Hosmer","year":"1999"},{"key":"10.3816\/CGC.2009.n.016_bib25","series-title":"Regression Methods in Biostatistics","first-page":"215","article-title":"Survival analysis: Cox proportional Hazards Model","author":"Vittinghoff","year":"2005"},{"key":"10.3816\/CGC.2009.n.016_bib26","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1097\/01.ju.0000059681.67567.12","article-title":"The predictive value of purified protein derivative results on complications and prognosis in patients with bladder cancer treated with bacillus Calmette-Guerin","volume":"169","author":"Bilen","year":"2003","journal-title":"J Urol"},{"key":"10.3816\/CGC.2009.n.016_bib27","series-title":"Statistical Methods in Diagnostic Medicine","first-page":"23","article-title":"Measures of diagnostic accuracy: the combined measures of sensitivity and specificity","author":"Zhou","year":"2002"},{"key":"10.3816\/CGC.2009.n.016_bib28","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.urolonc.2007.11.031","article-title":"Role of neutrophils in BCG immunotherapy for bladder cancer","volume":"26","author":"Simons","year":"2008","journal-title":"Urol Oncol"},{"key":"10.3816\/CGC.2009.n.016_bib29","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1007\/BF03262330","article-title":"The health economics of bladder cancer","volume":"21","author":"Bottelman","year":"2003","journal-title":"Pharmoeconomics"},{"key":"10.3816\/CGC.2009.n.016_bib30","series-title":"Cancer Prevention and Control","first-page":"69","article-title":"The economic burden of cancer","author":"Brown","year":"1995"},{"key":"10.3816\/CGC.2009.n.016_bib31","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1097\/00005650-199508000-00007","article-title":"Medicare payments from diagnosis to death for elderly cancer patients by stage at diagnosis","volume":"33","author":"Riley","year":"1995","journal-title":"Med Care"},{"key":"10.3816\/CGC.2009.n.016_bib32","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.urology.2007.08.014","article-title":"Economic impact of tumor markers in bladder cancer surveillance","volume":"71","author":"Hong","year":"2008","journal-title":"Urology"},{"key":"10.3816\/CGC.2009.n.016_bib33","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1097\/MOU.0b013e32830b8910","article-title":"Healthcare economics of bladder cancer: costenhancing and cost-reducing factors","volume":"18","author":"Noyes","year":"2008","journal-title":"Curr Opin Urol"},{"key":"10.3816\/CGC.2009.n.016_bib34","first-page":"35","article-title":"History of BCG and its substrains","volume":"310","author":"Crispen","year":"1989","journal-title":"Prog Clin Biol Res"},{"key":"10.3816\/CGC.2009.n.016_bib35","first-page":"391","article-title":"Interleukin-8: an expanding universe beyond neutrophil chemotaxis and activation","volume":"72","author":"Mukaida","year":"2000","journal-title":"Int J Hematol"},{"key":"10.3816\/CGC.2009.n.016_bib36","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1089\/107999099314234","article-title":"Human endothelium as a source of multifunctional cytokines: molecular regulation and possible role in human disease","volume":"19","author":"Krishnaswamy","year":"1999","journal-title":"J Interferon Cytokine Res"},{"key":"10.3816\/CGC.2009.n.016_bib37","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/BF01063773","article-title":"Cytokine gene expression on glioma cell lines and specimens","volume":"21","author":"Yamanaka","year":"1994","journal-title":"J Neurooncol"},{"key":"10.3816\/CGC.2009.n.016_bib38","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1002\/(SICI)1097-0215(19970917)72:6<937::AID-IJC3>3.0.CO;2-Q","article-title":"Expression of cytokine messenger RNA in normal and neoplastic human breast tissue: identification of interleukin-8 as a potential regulatory factor in breast tumours","volume":"72","author":"Green","year":"1997","journal-title":"Int J Cancer"},{"key":"10.3816\/CGC.2009.n.016_bib39","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1006\/gyno.1999.5358","article-title":"Increased IL-6 and IL-8 levels in cervicovaginal secretions of patients with cervical cancer","volume":"73","author":"Tjiong","year":"1999","journal-title":"Gynecol Oncol"},{"key":"10.3816\/CGC.2009.n.016_bib40","first-page":"2786","article-title":"Nuclear factor-kappaB mediates angiogenesis and metastasis of human bladder cancer through the regulation of interleukin-8","volume":"9","author":"Karashima","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CGC.2009.n.016_bib41","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S0090-4295(03)00134-1","article-title":"Urinary interleukin-8 levels are elevated in subjects with transitional cell carcinoma","volume":"62","author":"Sheryka","year":"2003","journal-title":"Urology"},{"key":"10.3816\/CGC.2009.n.016_bib42","doi-asserted-by":"crossref","first-page":"8250","DOI":"10.1158\/0008-5472.CAN-06-1416","article-title":"Neutrophil granulocytes are required for effective Bacillus Calmette-Gu\u00e9rin immunotherapy of bladder cancer and orchestrate local immune responses","volume":"66","author":"Suttmann","year":"2006","journal-title":"Cancer Res"},{"key":"10.3816\/CGC.2009.n.016_bib43","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1016\/S0022-5347(05)64361-3","article-title":"Urinary interleukin-8 predicts the response of standard and low dose intravesical bacillus Calmette-Guerin (modified Danish 1331 strain) for superficial bladder cancer","volume":"168","author":"Kumar","year":"2002","journal-title":"J Urol"},{"key":"10.3816\/CGC.2009.n.016_bib44","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1016\/S0022-5347(01)64111-9","article-title":"Urinary interleukin-8\/creatinine level as a predictor of response to intravesical bacillus Calmette-Guerin therapy in bladder tumor patients","volume":"158","author":"Rabinowitz","year":"1997","journal-title":"J Urol"},{"key":"10.3816\/CGC.2009.n.016_bib45","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1016\/S0022-5347(05)66983-2","article-title":"Urinary Interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Guerin","volume":"164","author":"Thalmann","year":"2000","journal-title":"J Urol"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767311700234?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767311700234?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:20:15Z","timestamp":1761564015000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767311700234"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,8]]},"references-count":45,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009,8]]}},"alternative-id":["S1558767311700234"],"URL":"https:\/\/doi.org\/10.3816\/cgc.2009.n.016","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2009,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Predictive Value of Urinary Interleukin-8 Cutoff Point for Recurrences After Transurethral Resection Plus Induction Bacillus Calmette-Gu\u00e9rin Treatment in Non\u2013Muscle-Invasive Bladder Tumors","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.3816\/CGC.2009.n.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}